Sometimes it's just hard to satisfy people. For them it's never enough. But the growth is stellar and solid. Last year $40m, this year $60m, next year $90m, then $135m and $200m. It does depend on the BARDA trial and diabetic foot ulcer trial and the sales in India, but all the pieces are in place.
Ann: NovoSorb MTX First Sales and March 2023 $6m Revenue, page-70
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.47 |
Change
0.120(5.11%) |
Mkt cap ! $1.706B | |||
| Open | High | Low | Value | Volume |
| $2.38 | $2.52 | $2.38 | $6.169M | 2.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3613 | $2.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.48 | 38844 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |